New Study Says Dalteparin May Not Be That Helpful for Pregnancy Complications
the MPR take:
A common blood thinner prescribed to pregnant women who have an increased risk of thromboembolic events such as preeclampsia many not actually be beneficial after all, reports a new study in The Lancet. An open-label randomized trial of 284 pregnant women compared antepartum use dalteparin vs. no antepartum dalteparin for the prevention of complications in pregnant women with thrombophilia. Use of dalteparin did not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications; minor bleeding was more commonly reported in the patients taking dalteparin compared to the no dalteparin group. Still, some experts say that dalteparin may still be beneficial to some patients, particularly those with prior severe preeclampsia or who gave birth to a child with severe low birth weight.
For the past 20 years pregnant women with an increased risk of developing blood clots have often been prescribed a common blood thinner to prevent serious complications from the clots, including preeclampsia (high blood pressure in the mother), disruption of the placenta, low birth weight and loss of the fetus. The largest randomized clinical trial to examine the therapy finds that the drug—low-molecular-weight heparin—is not effective.
READ FULL ARTICLE From Scientific American